Jpmorgan Chase & CO Infinity Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2023 Aug 11, 2023	BUY	$0.14 - $0.24 $1 - $3	13 Added 1.13%	1,160 $0
Q1 2023 May 11, 2023	SELL	$0.16 - $0.74 $243 - $1,127	-1,523 Reduced 57.04%	1,147 $0
Q4 2022 Feb 13, 2023	SELL	$0.46 - $1.21 $1,055 - $2,776	-2,295 Reduced 46.22%	2,670 $2,000
Q3 2022 Nov 14, 2022	BUY	$0.59 - $1.7 $669 - $1,929	1,135 Added 29.63%	4,965 $6,000
Q2 2022 Aug 11, 2022	SELL	$0.49 - $1.2 $23,419 - $57,354	-47,795 Reduced 92.58%	3,830 $2,000
Q1 2022 May 11, 2022	BUY	$0.85 - $2.4 $9,688 - $27,355	11,398 Added 28.33%	51,625 $59,000
Q4 2021 Feb 10, 2022	BUY	$1.86 - $3.36 $14,595 - $26,365	7,847 Added 24.23%	40,227 $91,000
Q3 2021 Nov 12, 2021	BUY	$1.52 - $3.82 $49,217 - $123,691	32,380 New	32,380 $110,000

1.26M

Ticker INFI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 89,277,904
Description
Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of met...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.